A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

• Status: Recruiting
• Trial end date: 2024-09-30

Summary

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma.

• Phase: Phase 3

Details

• Lead Sponsor: AbbVie
• Collaborator: Roche-Genentech
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Pomalidomide; Thalidomide; Venetoclax